British Journal of Pharmacology · 1987 · 83 citations · 28 references
MedicineCardiologyPharmacologyBiochemical PharmacologyMolecular PharmacologyPharmacodynamicsCardiovascular PharmacodynamicsCardiovascular PharmacologyCalcitonin Gene-related Peptide PhysiologyCalcitonin PharmacologyVascular Smooth Muscle PharmacologyVascular Smooth Muscle RegulationVascular Smooth Muscle RelaxationVasodilator Pharmacology
1 Ring segments of bovine left circumflex coronary artery were pre-contracted with 5-hydroxytryptamine or phenylephrine and then exposed to increasing concentrations of calcitonin gene-related peptide (CGRP) and other drugs. 2 CGRP administration resulted in dose-dependent inhibition of induced tone. Maximal relaxation to CGRP was 89 +/- 5% and the concentration required to achieve 50% maximal relaxation (EC50) was 2.11 +/- 1.35 X 10(-9)M. 3 CGRP-induced relaxation was not affected by removal of endothelial cells nor was it significantly altered by incubation of coronary vessels with atropine, propranolol, phentolamine (all 10(-6)M) or indomethacin (10(-5)M). 4 From these data we conclude that CGRP is a potent inhibitor of coronary artery vasomotor tone which appears to act directly on vascular smooth muscle rather than through the release of a secondary mediator. These data support the possibility that CGRP may play a role in non-adrenergic, non-cholinergic regulation of coronary artery tone.
28
Calcitonin gene-related peptide is a potent vasodilator
Susan D. Brain, T.J. Williams, John R. Tippins et al. · Nature · 1985 · 2.1K citations
Jan M. Lundberg, Anders Franco‐Cereceda, Xiao‐Ying Hua et al. · European Journal of Pharmacology · 1985 · 595 citations
Isolation and characterization of human calcitonin gene-related peptide
Howard R. Morris, Maria Panico, Tony Etienne et al. · Nature · 1984 · 426 citations